Clinical trial
Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With…
NCT02229851 · Novo Nordisk A/S, Industry · Completed
Key facts
| NCT number | NCT02229851 |
|---|---|
| Title | Trial to Compare the Efficacy and Safety of NNC0195-0092 (Somapacitan) With Placebo and Norditropin® FlexPro® (Somatropin) in Adults With Growth Hormone Deficiency. |
| Official title | A Multicentre, Multinational, Randomised, Parallel-group, Placebo-controlled (Double Blind) and Active-controlled (Open) Trial to Compare the Efficacy and Safety of Once Weekly Dosing of NNC0195-0092 (Somapacitan) With Once Weekly Dosing of Placebo and Daily Norditropin® FlexPro® in Adults With… |
| Acronym | REAL 1 |
| Lead sponsor | Novo Nordisk A/S, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Growth Hormone Disorder, Adult Growth Hormone Deficiency |
| Intervention type | Drug |
| Interventions | somapacitan, somatropin, placebo |
| Enrollment | 301 |
| Start date | Oct 31, 2014 |
| Primary completion | Apr 21, 2017 |
| Completion | May 7, 2018 |
| First posted | Sep 3, 2014 |
| Last update posted | Nov 23, 2020 |
| Countries | Australia, Brazil, Germany, India, Israel, Japan, Latvia, Lithuania, Malaysia, Norway, Poland, Romania and 7 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: